STOCK TITAN

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Kezar Life Sciences, Inc. (NASDAQ: KZR) announced the granting of nonqualified stock options to three employees, enabling them to purchase 12,000 shares at an exercise price of $4.86 per share, which matches the stock's closing price on June 1, 2022. The options will vest over four years, providing incentives for continued employment. This move adheres to Nasdaq Listing Rule 5635(c)(4) as an inducement for new hires.

Positive
  • Nonqualified stock options granted to three employees as an inducement award.
  • Options exercise price set at $4.86, equal to the stock closing price.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted three employees nonqualified stock options to purchase an aggregate of 12,000 shares of its common stock with an exercise price of $4.86 per share, which is equal to the closing price of Kezar’s common stock on June 1, 2022, the grant date of the awards. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms and conditions of Kezar’s 2022 Inducement Plan and the stock option agreement covering the grants.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

Gitanjali Jain

Vice President, Investor Relations and External Affairs

650-269-7523

gjain@kezarbio.com

Liza Sullivan

Argot Partners

212-600-1902

kezar@argotpartners.com

Source: Kezar Life Sciences, Inc.

FAQ

What stock options were granted by KZR?

Kezar Life Sciences granted nonqualified stock options for 12,000 shares at an exercise price of $4.86.

When did KZR announce the stock options grant?

The announcement was made on June 1, 2022.

How long is the vesting period for KZR's stock options?

The stock options will vest over a four-year period.

What is the purpose of the stock options granted by KZR?

The options were granted as an inducement for new employees.

Are KZR's stock options related to Nasdaq rules?

Yes, the grant adheres to Nasdaq Listing Rule 5635(c)(4) for inducement awards.

Kezar Life Sciences, Inc.

NASDAQ:KZR

KZR Rankings

KZR Latest News

KZR Stock Data

47.21M
6.02M
14.8%
63.9%
2.44%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO